Biopharma IT Jobs Face Fiercest Competition

IT professionals seeking positions in biopharma faced the toughest competition of any function in 2025, with applications outpacing available jobs by 6.8 times on average—nearly double the industry-wide rate. The grim reality contradicts expectations of a tech hiring surge, as job postings declined and layoffs accelerated throughout the year.

BioSpace data reveals that every single month in 2025, applications for IT positions far exceeded available openings in the biopharma sector. While other functions like science/R&D saw 4.4 applications per job and quality assurance averaged 2.9, IT professionals battled nearly 7 applicants for every single posting.

The competitive pressure intensified as 42,700 biopharma employees lost their jobs in 2025—a 47% year-over-year increase—flooding the market with experienced professionals scrambling for limited opportunities. Summer months proved especially brutal, with May through July accounting for 15,200 layoffs across 68 companies, representing 36% of the year's total cuts.

"Very few jobs available with a huge pool of candidates looking for a job," one biopharma professional wrote in a BioSpace survey conducted late last year. "Every job post had hundreds of candidates applying."

Technology and AI/ML roles ranked as the second-most sought-after function among employed workers (26%) and third among unemployed professionals (24%) surveyed by BioSpace. Yet despite strong demand from job seekers, companies dramatically curtailed IT hiring throughout 2025.

What's Driving the Flood of IT Applicants?

The biopharma IT job market deteriorated sharply in 2025 as layoffs hit companies across the sector. Major pharmaceutical giants including Bayer, Bristol Myers Squibb, Merck, Novo Nordisk, and CSL announced workforce reductions totaling thousands of positions.

Bayer cut approximately 4,450 employees through Q3 2025 as part of its Dynamic Shared Ownership restructuring aimed at saving $2.3 billion by 2026. Bristol Myers Squibb eliminated over 1,000 positions in the first half alone, including 516 at its Lawrenceville, New Jersey headquarters. Merck unveiled plans to slash 6,000 jobs—8% of its workforce—by the end of 2027 to save $3 billion annually.

The cuts weren't limited to Big Pharma. Novo Nordisk announced a massive global restructuring affecting 9,000 employees, including roughly 5,000 in Denmark and significant US layoffs targeting HR, regulatory, legal, medical, and compliance functions. Teva Pharmaceuticals revealed plans to cut 2,900 employees worldwide by 2027.

Capital constraints drove much of the carnage. "After a wave of early-stage biotech failures, investors rotated out of the sector, which significantly constrained funding," Eric Celidonio, founder and managing partner of Sci.bio Recruiting, told BioSpace. "As capital tightened, early-stage companies had to get lean, while larger biopharma focused on acquiring late-development biotechs for core assets and key R&D talent."

Smaller biotechs suffered disproportionately. Leap Therapeutics announced in May it would cut roughly half its workforce—24 employees—then slashed another 75% of remaining staff in June, leaving fewer than 10 people. Atara Biotherapeutics eliminated 50% of its workforce in January, then cut another 50% in March. Seven companies—including Velia Therapeutics, Oxular, and Viracta Therapeutics—shut down entirely, eliminating all positions.

The summer months proved particularly devastating. Applications peaked during May, June, and July when they ran 4.3x, 4.7x, and 4.6x higher than jobs live on BioSpace, respectively. The surge coincided with industry layoffs hitting their 2025 peak, as dozens of companies simultaneously cut staff. May alone saw 29 different companies report workforce reductions—an all-time monthly high.

Pipeline failures accelerated the cuts. Companies that received massive COVID-era funding expanded rapidly in 2020-2021, then faced disappointing clinical trial results in 2024-2025. The wave of program failures forced biotechs to eliminate entire departments, hitting IT infrastructure teams particularly hard as companies scaled back technology investments alongside R&D reductions.

Department of Health and Human Services cuts in early 2025 compounded the problem, flooding the market with experienced regulatory, compliance, and IT professionals from federal agencies. While some HHS workers were eventually rehired, the temporary influx added thousands more applicants competing for private sector biopharma roles.

Artificial intelligence played a secondary but meaningful role in the workforce reductions. "As AI tools increasingly support discovery, clinical operations, regulatory work and corporate functions, leadership teams reassess how much incremental hiring is truly necessary," Audrey Greenberg, CEO of AG Capital Advisors, explained to BioSpace. "In a capital-constrained environment, that reassessment favored leaner operating models and reduced the urgency to backfill roles."

The shift toward AI-enabled operations particularly affected IT hiring. Companies implementing machine learning platforms for drug discovery, automated data management systems, and AI-assisted clinical trial monitoring questioned whether they needed as many database administrators, systems engineers, and IT support staff. The technology that IT professionals helped implement ultimately reduced demand for their own positions.

How Bad Is the Overall Biopharma Job Market?

Job postings on BioSpace declined year-over-year in every single month of 2025, hitting their lowest point in August at just 6,385 positions—down 32% from the previous year. Average monthly job postings followed the same downward trajectory, dropping to 2,903 in August, the lowest figure for 2025.

Meanwhile, applications surged. In July alone, nearly 34,000 applications competed for roughly 7,400 jobs—the third-largest gap between measures for the year. Applications jumped 243% year-over-year that month, signaling desperate competition for shrinking opportunities.

The pattern persisted through year's end. December 2025 saw average job postings decline 10% month-over-month and 16% year-over-year—typical holiday slowdowns amplified by broader market weakness. A spike in early January 2026 offered modest hope, with postings increasing 5% from December, though still well below historical norms.

Quarterly data painted an equally dismal picture. Q1 2025 job postings dropped 20% year-over-year while applications spiked 91%. Q2 saw postings decline 15% with applications jumping 79%. The third quarter brought postings down record amounts with applications continuing to vastly outpace opportunities.

Even employed biopharma professionals sought exits. According to the BioSpace 2026 U.S. Life Sciences Employment Outlook report, 52% of employed/contract respondents were actively job hunting late last year—up from 46% in 2024. Looking ahead to 2026, 64% said they'll actively search for new positions, compared with 59% who planned to do so in 2025.

Among unemployed respondents, 93% were actively seeking employment when surveyed, with 96% planning to continue their search in 2026. Alarmingly, 85% of unemployed survey participants indicated they're considering roles outside biopharma entirely.

"Don't see biopharma as a viable long term career opportunity any longer," one survey participant wrote. Another reflected bitterly: "There is zero job security in biopharma. I'm an experienced professional with over a decade of industry experience. I wish I had picked a different field of study and work."

The frustration extended to IT professionals specifically. "Worried that a typical Research/Discovery leadership job is almost impossible to find due to extreme numbers of unemployed scientists," one respondent commented, while another described the market as "an exhausting race for survival."

Are Any Companies Still Hiring IT Professionals?

Despite the bleak landscape, some major biopharma companies continue recruiting IT talent—though competition remains fierce for every opening. AbbVie, Amgen, Eli Lilly, Takeda, and BioMarin all maintain active job postings across IT functions.

AbbVie posted over 200 open positions in early January 2026, including IT roles like IT technical specialist (marketing data) in Mettawa, Illinois and various technical positions at North Chicago facilities. Amgen offered approximately 10 openings including technology and data engineering roles in Thousand Oaks, California and South San Francisco.

Eli Lilly maintained dozens of IT-related positions ranging from data scientist roles in gene therapy to automation engineering positions in Indianapolis. The company's openings span IT architecture, data engineering, process control, and automation—core functions as drug discovery and manufacturing increasingly depend on technology infrastructure.

Takeda advertised dozens of opportunities including remote positions and Boston-area roles focusing on computational biology, data science, and AI applications in drug discovery. The company's IT hiring emphasized emerging technologies like predictive analytics and machine learning integration into pharmaceutical R&D.

BioMarin and other companies increasingly offered remote IT positions, allowing candidates nationwide to compete for roles without geographic constraints. However, this geographic flexibility intensified competition further, as a single remote posting attracted applications from across the country rather than just local markets.

California and Massachusetts—traditional biopharma hubs—saw the highest concentration of IT openings. Yet even in these biotech hotspots, postings declined sharply from previous years. California had 58 companies making or projecting cuts in 2025, while Massachusetts saw 56—the two highest state totals for layoffs.

Industry experts remain cautiously optimistic about 2026. Greg Clouse, BioSpace recruitment manager, noted in February 2025 that companies finally backed up hopeful rhetoric with actual hiring plans. "Most of the companies I talked to are expecting to do some hiring this year," he said. "They're not going to do a ton of hiring like they did two or three years ago when they were scrambling to get people, but they are going to do some hiring."

The fourth quarter of 2025 showed early stabilization signs, with layoffs affecting 3,603 employees—down 47.1% from Q4 2024's 6,814. Some analysts predict the worst may have passed. "Broad-based increases in layoffs are less likely this year, as significant structural correction has already occurred and public biotech performance has begun to improve," Greenberg told BioSpace.

Still, IT professionals face an uphill battle. With 6.8 applications for every job posting throughout 2025 and thousands of experienced professionals displaced by layoffs, landing a biopharma IT role in 2026 demands persistence, strategic networking, and often willingness to accept contract positions or roles outside core therapeutic development.

People Also Asked

Q: Why is competition so fierce for biopharma IT jobs compared to other functions? IT roles saw 6.8 applications per job in 2025—nearly double the science/R&D rate of 4.4x and far exceeding quality assurance's 2.9x ratio. Technology professionals face heightened competition because 26% of employed workers and 24% of unemployed professionals actively seek IT positions, while companies simultaneously reduced hiring as AI tools automated some functions and capital constraints forced leaner operating models.

Q: Which biopharma companies had the largest layoffs affecting IT professionals in 2025?Novo Nordisk led with 9,000 global cuts including significant US reductions in IT, HR, regulatory, and compliance. Merck announced 6,000 planned job cuts through 2027. Bayer eliminated approximately 4,450 positions through Q3 2025. Bristol Myers Squibb cut over 1,000 employees in the first half alone, while Teva projected 2,900 worldwide cuts by 2027. Major layoffs also hit CSL, Sarepta, and dozens of smaller biotechs.

Q: Will the biopharma IT job market improve in 2026? Industry experts anticipate modest improvement but caution against expecting dramatic recovery. Early January 2026 showed job postings up 5% from December 2025, though still well below historical levels. The XBI biotech index recovered 30%+ in late 2025, suggesting improving investor sentiment. However, with 64% of employed biopharma professionals planning active job searches in 2026 and thousands of 2025 layoff victims still seeking work, IT competition will likely remain intense throughout the year despite gradual stabilization.

Looking for verified biopharma IT roles? Visit Metaintro to access real-time job opportunities from 600+ million global postings across 120+ countries.